Istanbul Acıbadem Dr Sinasi Can Kadikoy Healthcare Group, Department of Obstetrics and Gynecology, Istanbul, Turkey
Non-endometrioid endometrial carcinoma seems to be less common with a poor prognosis. Due to the lack of standard treatment options and worse survival rates of non-endometrioid endometrial carcinoma, we aimed to investigate these patients inclusively. In total, 492 women with endometrial cancer who were treated in a gynecologic oncology center were examined. Patients with a final histopathologic diagnosis of non-endometrioid endometrial carcinoma were evaluated in respect of demographic characteristics, prognostic aspects, and survival outcomes. We identified 94 patients with the histopathologic results of non-endometrioid endometrial carcinoma. The performance of the systematic lymphadenectomy and adjuvant treatment rate were 96.9% and 92.6%, respectively. Recurrence of the disease was detected in 32 (34%) women and disease-related mortality occurred in 28 (29.8%) women. Multivariate Cox proportional regression analyses determined tumor size, adnexal involvement, and lymphovascular space invasion as independent predictors of overall survival. Larger tumor size, adnexal, and lymphovascular space invasion are important factors in determining prognosis in non-endometrioid endometrial carcinoma patients according to our findings. Besides, high rates of surgical staging and adjuvant chemotherapy and radiation therapy may contribute to improved survival outcomes; in addition to having potential advantages of providing prognostic information. Therefore, a multidisciplinary therapeutic approach should be planned from the early stages for all patients in this group. Nevertheless, comprehensive prospective studies are necessary to optimize the treatment strategies and support successful treatment modalities.
Keywords: Comprehensive staging, endometrial carcinoma, non-endometrioid carcinoma, survival
Conflict of interests: The authors declare that there is no conflict of interest in the study.
Financial Disclosure: The authors declare that they have received no financial support for the study.
Ethical approval: Approval of the study was obtained from the Institutional Review Board (Project number KA 20/311, approval date 11 August 2020).
2,603 total views, 1 views today
Baran SY, Alemdaroglu S, Dogan Durdag G, et al. Survival analyses of patients with non-endometrioid endometrial carcinoma. Med Science. 2022;11(3):1242-7.
⇓ PlumX Meter
Corresponding Author: Sirin Aydin, Adana Başkent University, Dr. Turgut Noyan Application and Research Center, Department of Obstetrics and Gynecology, Adana, Turkey .